Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches

doi:10.3390/ijms232113287

Article

Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches

31 Oct 2022

Abstract excerpt

Continuous development of personalized treatments is undoubtedly beneficial for oncogenic patients’ comfort and survival rate. Mutant TP53 is associated with a worse prognosis due to the occurrence of metastases, increased chemoresistance, and tumor growth. Currently, numerous compounds capable of p53 reactivation or the destabilization of mutant p53 are being investigated. Several of them, APR-246, COTI-2, SAHA,...

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.